These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26323538)

  • 1. PCSK9 inhibitors are go.
    Mullard A
    Nat Rev Drug Discov; 2015 Sep; 14(9):593. PubMed ID: 26323538
    [No Abstract]   [Full Text] [Related]  

  • 2. PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
    EBioMedicine
    EBioMedicine; 2015 Dec; 2(12):1835. PubMed ID: 26844247
    [No Abstract]   [Full Text] [Related]  

  • 3. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM; Smith RJ; Hiatt WR
    N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
    [No Abstract]   [Full Text] [Related]  

  • 4. [First PCSK9 inhibitor].
    Westphal K
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27462666
    [No Abstract]   [Full Text] [Related]  

  • 5. [First PCSK9 inhibitor].
    Westphal K
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324017
    [No Abstract]   [Full Text] [Related]  

  • 6. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
    Lettino M
    G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
    [No Abstract]   [Full Text] [Related]  

  • 7. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 8. [2nd PCSK9 inhibitor for effective LDL decrease].
    Einecke D
    MMW Fortschr Med; 2016 Feb; 158(2):65. PubMed ID: 26961048
    [No Abstract]   [Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK; Jensen HK
    Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promises of PCSK9 inhibition.
    Petrides F; Shearston K; Chatelais M; Guilbaud F; Meilhac O; Lambert G
    Curr Opin Lipidol; 2013 Aug; 24(4):307-12. PubMed ID: 23817198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How far down to push the LDL cholesterol? PCSK9 where statins fail.
    Simko V; Ginter E
    Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 14. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding the Right Price for Improving Care.
    Charlton B
    JAMA Intern Med; 2016 Jan; 176(1):109. PubMed ID: 26662340
    [No Abstract]   [Full Text] [Related]  

  • 18. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
    Norata GD; Tibolla G; Catapano AL
    Vascul Pharmacol; 2014 Aug; 62(2):103-11. PubMed ID: 24924410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk of cardiovascular complications cut in half?].
    Einecke D
    MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190
    [No Abstract]   [Full Text] [Related]  

  • 20. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.